The effect of Xuezhikang capsule combined with alirocumab on the degree of atherosclerosis and blood lipid levels in patients with atherosclerotic cardiovascular disease intolerant to statins

Wu Jieqiong; Li Hongyue; Wang Jiaxing; Tian Dandan; Liu Yuhui; Ni Chen; Geng Qingfeng; Qian Yun

doi:10.3760/j.issn.1673-4777.2025.05.005

Abstract：Objective To investigate the effects of Xuezhikang capsule combined with alirocumab on the degree of atherosclerosis and blood lipid levels in patients with atherosclerotic cardiovascular disease(ASCVD)intolerant to statins.Methods Eighty ASCVD patients with statin intolerance admitted to the Second Affiliated Hospital of Hebei University of Chinese Medicine from June 2022 to August 2024 were enrolled.According to random number table method,they were divided into observation group(41 cases)and control group(39 cases).The control group was treated with alirocumab.The observation group was treated with Xuezhikang capsule on the basis of the control group.Both groups were treated for 12 weeks.The degree of arteriosclerosis,blood lipid indexes,the standard-reaching rate of low-density lipoprotein cholesterol(LDL-C),the standard-reaching rate of LDL-C reduction＞50％,the incidence of adverse reactions and the total effective rate were compared between the two groups after treatment.Results After 4,8 and 12 weeks of treatment,the levels of LDL-C,triglyceride,total cholesterol,creatine kinase,glutamate,creatine kinase isoenzyme,cardio-ankle vascular index and brachial-ankle pulse wave velocity in the observation group were significantly lower than those in the control group;high density lipoprotein cholesterol,lipoprotein a,total bilirubin,aspartate aminotransferase,alanine aminotransferase,and ankle brachial index were higher than those in the control group(all P＜0.05).The compliance rate of LDL-C,the compliance rate of LDL-C reduction＞50％and the total effective rate in the observation group were higher than those in the control group[78.0％(32/41)vs 35.9％(14/39),95.1％(39/41)vs 41.0％(16/39),97.6％(40/41)vs 79.5％(31/39)](all P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P=0.107).Conclusion Xuezhikang capsule combined with alirocumab in the treatment of ASCVD patients with statin intolerance can significantly improve the degree of atherosclerosis and the rate of LDL-C reaching the standard,with significant clinical efficacy and high safety.